Randomized, Double-masked, Parallel-group, Phase 1 Study, to Compare CMAB807 Injection to Prolia ® in Healthy Volunteers

Condition:   Postmenopausal Osteoporosis Interventions:   Drug: Prolia®;   Drug: CMAB807 Sponsor:   Shanghai Biomabs Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials